MXPA04000993A - MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO. - Google Patents
MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO.Info
- Publication number
- MXPA04000993A MXPA04000993A MXPA04000993A MXPA04000993A MXPA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A MX PA04000993 A MXPA04000993 A MX PA04000993A
- Authority
- MX
- Mexico
- Prior art keywords
- nitric oxide
- mammalian cells
- mammals
- pulmonary disease
- indigenous
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 208000019693 Lung disease Diseases 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title abstract 3
- 238000001727 in vivo Methods 0.000 title abstract 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 16
- 210000004962 mammalian cell Anatomy 0.000 abstract 5
- 239000002243 precursor Substances 0.000 abstract 3
- 150000004716 alpha keto acids Chemical class 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 abstract 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a un metodo para tratar una enfermedad pulmonar en mamiferos mediante la alteracion in vivo de los niveles normales del oxido nitrico en celulas de mamiferos. El metodo comprende contactar las celulas de mamiferos con una cantidad terapeuticamente efectiva de un mediador de oxido nitrico seleccionado del grupo que consiste de piruvatos, precursores de piruvato, a-ceto acidos que tiene cuatro o mas atomos de carbono, precursores de a-ceto acidos que tienen cuatro o mas atomos de carbono y las sales de los mismos. El metodo ademas comprende contactar las celulas de mamiferos con un agente terapeutico y una fuente de oxido nitrico seleccionada del grupo que consiste de oxido nitrico, precursores del oxido nitrico y estimuladores del oxido nitrico. En otra modalidad, el metodo comprende tratar una enfermedad pulmonar en mamiferos mediante proteger los niveles normales in vivo del oxido nitrico en las celulas de mamiferos durante la inhalacion de ozono mediante contactar las celulas de mamiferos con una cantidad terapeuticamente efectiva de un mediador de oxido nitrico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31387201P | 2001-08-21 | 2001-08-21 | |
| PCT/US2002/026060 WO2003017996A1 (en) | 2001-08-21 | 2002-08-15 | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04000993A true MXPA04000993A (es) | 2004-04-20 |
Family
ID=23217517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04000993A MXPA04000993A (es) | 2001-08-21 | 2002-08-15 | MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6689810B2 (es) |
| EP (1) | EP1427402A4 (es) |
| JP (1) | JP2005501106A (es) |
| AU (1) | AU2002329762B2 (es) |
| CA (1) | CA2457983C (es) |
| IL (1) | IL159898A0 (es) |
| MX (1) | MXPA04000993A (es) |
| WO (1) | WO2003017996A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
| US9486429B2 (en) * | 1999-06-01 | 2016-11-08 | Vanderbilt University | Therapeutic methods employing nitric oxide precursors |
| US6346382B1 (en) | 1999-06-01 | 2002-02-12 | Vanderbilt University | Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto |
| JP2003048831A (ja) * | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| US20030105162A1 (en) * | 2001-08-21 | 2003-06-05 | Celluar Sciences, Inc. | Method for treating bronchial constriction and bronchospasm |
| US20040220265A1 (en) * | 2002-07-25 | 2004-11-04 | Celluar Sciences, Inc. | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| US8076373B2 (en) * | 2001-09-11 | 2011-12-13 | North Cell Pharmacetical | Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite |
| US20080213403A1 (en) * | 2002-07-25 | 2008-09-04 | Alain Martin | Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide |
| DK1542670T3 (da) * | 2002-09-24 | 2013-05-27 | Suntory Holdings Ltd | Sammensætning omfattende arachidonsyre alene eller i kombination med docosahexanoensyre til forøgelse af kognitive evner hos voksne |
| CA2413834A1 (en) * | 2002-12-10 | 2004-06-10 | 1017975 Alberta Limited | Nitric oxide gas generator |
| US9138707B2 (en) | 2002-12-10 | 2015-09-22 | Sy Kimball | Portable, nitric oxide generator |
| JP4522075B2 (ja) * | 2003-10-29 | 2010-08-11 | サントリーホールディングス株式会社 | 血管の老化に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| US8017074B2 (en) | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
| EP1701747B1 (en) | 2004-01-07 | 2014-03-12 | Noxilizer, Inc. | Sterilisation method |
| CA2557814A1 (en) * | 2004-03-01 | 2005-09-15 | Lumen Therapeutics, Llc | Compositions and methods for treating diseases |
| US20080008771A1 (en) * | 2004-05-27 | 2008-01-10 | Children's Hospital Medical Center | Nitric Oxide Dioxygenase Inhibitors |
| JP2006083136A (ja) * | 2004-09-17 | 2006-03-30 | Suntory Ltd | ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| CA2589995C (en) * | 2004-12-17 | 2016-01-05 | Alan B. Cash | Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for treating cancer |
| JP5697293B2 (ja) * | 2005-06-30 | 2015-04-08 | サントリーホールディングス株式会社 | 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物 |
| JP5967855B2 (ja) * | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| US20090018091A1 (en) | 2005-08-02 | 2009-01-15 | Nitromed, Inc. | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use |
| EP1986952A4 (en) * | 2006-02-22 | 2011-03-30 | Puricore Inc | METHOD FOR THE TREATMENT OF MUCOVISCIDOSIS |
| WO2007126609A1 (en) | 2006-03-29 | 2007-11-08 | Nitromed, Inc. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
| US8114907B2 (en) * | 2007-08-08 | 2012-02-14 | Cellular Sciences Inc | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| US8211943B2 (en) * | 2007-08-08 | 2012-07-03 | Alain Martin | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| US9675569B2 (en) * | 2007-08-08 | 2017-06-13 | Alain Martin | Method for treating a pulmonary disease state in mammals by up regulating indigenous in vivo levels of inflammatory agents in mammalian cells |
| RU2528097C2 (ru) * | 2008-01-31 | 2014-09-10 | Вандербилт Юнивёсити | Способы и составы для лечения субарахноидального кровоизлияния коронарной и артериальной аневризмы |
| HUE043235T2 (hu) * | 2008-01-31 | 2019-08-28 | Univ Vanderbilt | Terápiás kezelések tüdõbetegségekhez |
| WO2010017633A1 (en) * | 2008-08-13 | 2010-02-18 | Chris Miller | Use of nitric oxide |
| CA2737695C (en) * | 2008-09-22 | 2018-10-23 | Geno Llc | Conversion of nitrogen dioxide (no2) to nitric oxide (no) |
| AU2010215774B2 (en) | 2009-02-23 | 2015-05-21 | Noxilizer, Inc. | Device and method for gas sterilization |
| DK3398594T3 (da) | 2012-09-19 | 2024-09-23 | Grespo Ab | Sammensætninger til forbedring af hjernefunktion |
| US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
| CN105492906B (zh) * | 2013-06-14 | 2017-08-25 | 首尔大学校产学协力团 | 花生四烯酸或其衍生物在检测阻塞性睡眠呼吸暂停中的用途 |
| EP3936145A1 (en) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| WO2017132275A1 (en) | 2016-01-27 | 2017-08-03 | Syk Technologies, Llc | Nitric oxide topical application apparatus and methods |
| US11311505B2 (en) * | 2017-02-24 | 2022-04-26 | Cellular Sciences, Inc. | Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts |
| US20200237815A1 (en) * | 2017-02-24 | 2020-07-30 | Alain Martin | Methods for treatment of lung damage and for inhibition of lung fibrosis |
| US20220273686A1 (en) * | 2019-08-06 | 2022-09-01 | Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. | Pharmaceutical composition for producing safe amount of nitric oxide and use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158883A (en) * | 1989-09-13 | 1992-10-27 | Cornell Research Foundation, Inc. | Method of using aminoarginine to block nitric oxide formation in vitro |
| EP0441119A3 (en) * | 1990-01-09 | 1992-10-14 | Richard D. Levere | The use of l-arginine in the treatment of hypertension and other vascular disorders |
| US5147854A (en) * | 1990-05-22 | 1992-09-15 | Hoffmann-La Roche Inc. | Tgf-b compositions and method |
| US5296370A (en) * | 1990-10-04 | 1994-03-22 | Rutgers, The State University | Repair medium for the resuscitation of injured cells |
| US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| US5798388A (en) * | 1996-09-06 | 1998-08-25 | Cellular Sciences, Inc. | Method and composition for treating mammalian diseases caused by inflammatory response |
| MX9703653A (es) * | 1995-09-19 | 1998-07-31 | Cellular Sciences Inc | Composicion y metodo para tratar enfermedades mamiferas ocasionadas por la respuesta inflamatoria. |
-
2002
- 2002-07-25 US US10/205,353 patent/US6689810B2/en not_active Expired - Lifetime
- 2002-08-15 MX MXPA04000993A patent/MXPA04000993A/es active IP Right Grant
- 2002-08-15 CA CA2457983A patent/CA2457983C/en not_active Expired - Lifetime
- 2002-08-15 EP EP02766007A patent/EP1427402A4/en not_active Withdrawn
- 2002-08-15 IL IL15989802A patent/IL159898A0/xx unknown
- 2002-08-15 AU AU2002329762A patent/AU2002329762B2/en not_active Ceased
- 2002-08-15 JP JP2003522516A patent/JP2005501106A/ja active Pending
- 2002-08-15 WO PCT/US2002/026060 patent/WO2003017996A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US6689810B2 (en) | 2004-02-10 |
| JP2005501106A (ja) | 2005-01-13 |
| WO2003017996A1 (en) | 2003-03-06 |
| AU2002329762B2 (en) | 2007-03-01 |
| US20030040542A1 (en) | 2003-02-27 |
| CA2457983A1 (en) | 2003-03-06 |
| EP1427402A4 (en) | 2007-12-05 |
| IL159898A0 (en) | 2004-06-20 |
| EP1427402A1 (en) | 2004-06-16 |
| CA2457983C (en) | 2011-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04000993A (es) | MeTODO PARA TRATAR ENFERMEDADES PULMONARES EN MAMIFEROS MEDIANTE LA ALTERACION DE NIVELES NORMALES IN VIVO DE OXIDO NITRICO. | |
| GB0004153D0 (en) | Novel use | |
| MXPA03010142A (es) | Nuevos derivados de arilheteroalquilamina. | |
| MXPA03008223A (es) | Compuesto para tratamiento de enfermedades inflamatorias. | |
| AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
| TNSN03144A1 (en) | Pyrrolopyrimidines as protein kinase inhibitors | |
| PL365285A1 (en) | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs | |
| LT3449934T (lt) | Ii tipo glikogeno kaupimo ligos gydymas | |
| SE9803518D0 (sv) | Novel compounds | |
| NZ510920A (en) | Use of (S)-3-(aminomethyl)-5-methylhexanoic acid (pregabalin) to treat acute and chronic mania in humans | |
| AU2003278667A1 (en) | Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines | |
| MX2024003770A (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| SE9803773D0 (sv) | Compounds | |
| DE69707372D1 (de) | Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne | |
| SE0004101D0 (sv) | New use | |
| NZ519722A (en) | Treatment of diabetic ulcers | |
| MXPA03010205A (es) | Derivados de acido oxalico. | |
| GB0004152D0 (en) | Novel compounds | |
| CA2328348A1 (en) | 2-methylpropionic acid derivatives and medicinal compositions containing the same | |
| DE60210981D1 (de) | Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase | |
| SE0102639D0 (sv) | Novel compounds | |
| SE0102640D0 (sv) | Novel compounds | |
| GB0004151D0 (en) | Novel use | |
| SE0103325D0 (sv) | Novel compounds | |
| ATE447953T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |